$60 Degrees Pharmaceuticals (SXTP.US)$ Investigational Revie...
$60 Degrees Pharmaceuticals (SXTP.US)$ Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma's double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis patients
The previously announced Type C meeting with FDA has been rescheduled by FDA from January 15 to January 17, 2024, due to a federal holiday
The previously announced Type C meeting with FDA has been rescheduled by FDA from January 15 to January 17, 2024, due to a federal holiday
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
